STOCK TITAN
  1. Home
  2. Sec-filings
  3. NRSN
  4. [EFFECT] NeuroSense Therapeutics Ltd. SEC Filing

[EFFECT] NeuroSense Therapeutics Ltd. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 25, 2025 4:00 P.M.
Form: F-3
CIK: 0001875091
Company Name: NeuroSense Therapeutics Ltd.
File Number: 333-291122

Source: View Original Filing on SEC EDGAR

Stock NRSN logo
Neurosense Therapeutics Ltd

NASDAQ:NRSN

NRSN Rankings

#5829 Ranked by Market Cap
N/A Ranked by Dividends

NRSN Latest News

Jan 8, 2026
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Dec 22, 2025
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
Dec 4, 2025
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
Nov 24, 2025
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Nov 3, 2025
NeuroSense to Host Investor Webinar on December 8, 2025

NRSN Latest SEC Filings

Dec 8, 2025
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)
Nov 24, 2025
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)
Nov 21, 2025
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)
Oct 28, 2025
[F-3] NeuroSense Therapeutics Ltd. Foreign Issuer Shelf Registration
Oct 6, 2025
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)

NRSN Stock Data

31.78M
23.30M
29.68%
1.8%
1.09%
Biotechnology
Healthcare
Link
Israel
Herzliya